These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37724699)

  • 1. A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil.
    Wang Y; Zhao B; Yang H; Wan Z
    Andrology; 2024 May; 12(4):785-792. PubMed ID: 37724699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
    Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
    Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
    Liu Y; Dong C; He X; Shu Y; Wu P; Zou J
    J Pharm Pharm Sci; 2022; 25():377-390. PubMed ID: 36608646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
    Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
    Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacovigilance study of FDA adverse events for sugammadex.
    Mao X; Zhang R; Liang X; Liu F; Dai Y; Wang M; Huang H; Fu G
    J Clin Anesth; 2024 Oct; 97():111509. PubMed ID: 38880003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
    Li Y; Sun S; Wu H; Zhao L; Peng W
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):71. PubMed ID: 39334280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab.
    Yun X; Zhou Y; Wu D; Liu Y; Wu Q
    Expert Opin Drug Saf; 2024 May; 23(5):581-591. PubMed ID: 38600747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
    Liu W; Du Q; Guo Z; Ye X; Liu J
    Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.
    Zhu Z; Liu M; Zhang H; Zheng H; Li J
    Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38743462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database.
    Li S; Huang R; Meng Y; Liu Y; Qian J; Zou J; Yang J
    Front Pharmacol; 2024; 15():1420126. PubMed ID: 39161895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.
    Wu J; Wu J; Tang B; Wang X; Wei F; Zhang Y; Li L; Li H; Wang B; Wu W; Hong X
    Front Pharmacol; 2024; 15():1399172. PubMed ID: 39309013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database.
    Cui S; Li L; Liu W; Zhao B; Zhong X
    Braz J Med Biol Res; 2024; 57():e13392. PubMed ID: 39082578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Real-World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database.
    Hai L; Wu J; Xie Y
    Pharmacoepidemiol Drug Saf; 2024 Oct; 33(10):e70037. PubMed ID: 39420647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).
    Tang H; Xu J; Zhang X; Chen C; Song G; Ma R; Zhao J; Zhao Q
    Front Pharmacol; 2024; 15():1463560. PubMed ID: 39372199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
    Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
    Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.
    Dong S; Guo X; Wang H; Sun C
    Ther Adv Respir Dis; 2024; 18():17534666231223606. PubMed ID: 38179676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax.
    Yang Y; Shu Y; Chen G; Yin Y; Li F; Li J
    PLoS One; 2022; 17(12):e0278725. PubMed ID: 36477747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS).
    Liu D; Mao W; Hu B; Li X; Zhao Q; Zhang L; Hu J
    Front Pharmacol; 2024; 15():1405023. PubMed ID: 38983914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.